Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis
NCT00447837 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective of the study is to evaluate the safety and efficacy of SPRC-AB01 versus placebo for treatment of chronic sinusitis in subjects who have had sinus surgery.
Conditions Studied
Interventions
- DRUG SPRC-AB01
Study Locations (20)
California
- Central California Clinical Research — Fresno
- Allergy Research Foundation, Inc — Los Angeles
- Children's Hospital of Orange County — Orange
- Allergy Medical Group of the North Area Inc — Roseville
- Sacramento Ear, Nose & Throat — Sacramento
- Allergy & Asthma Medical Group and Research Center — San Diego
Florida
- Clinical Trials Management LLC — Boca Raton
- Allergy & Asthma Center / South Florida ENT — Fort Lauderdale
- Clinical Research of West Florida — Tampa
Georgia
- Nasal Sinus and Allergy Institute — Alpharetta
- Northeast Georgia Research Center — Gainsville
- Northside Ear, Nose & Throat — Roswell
Colorado
- 1st Allergy & Clinical Research Center — Centennial
- Colorado Otolaryngology Associates — Colorado Springs
Alabama
- Clinical Research Consultants — Hoover
Arkansas
- NEA Clinic — Jonesboro
Connecticut
- The Connecticut Sinus Center — Bridgeport
Kentucky
- Commonwealth Ear, Nose & Throat — Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00447837
The ClinicalTrials.gov registry entry for NCT00447837 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Naryx Pharma, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Chronic Sinusitis appearing as the primary indexed condition, and to 1 intervention — of which SPRC-AB01 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00447837 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00447837 about?
NCT00447837 is a clinical study titled "Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis". The primary objective of the study is to evaluate the safety and efficacy of SPRC-AB01 versus placebo for treatment of chronic sinusitis in subjects who have had sinus surgery.
What is the current status of trial NCT00447837?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2006-10. Estimated completion is 2008-01.
What conditions does trial NCT00447837 study?
This clinical trial studies the following conditions: Chronic Sinusitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00447837?
The interventions under investigation include: SPRC-AB01 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00447837?
This trial is sponsored by Naryx Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00447837 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.